fbpx Back to Top

Metastatic Breast Cancer

Get Help with Your Treatment

Apply Online or call 1-866-316-7263


Program Status

Currently Closed – We are no longer accepting or processing applications for new or renewal patients.


The PAN Foundation’s Metastatic Breast Cancer fund is currently closed. As of January 7, 2019, CancerCare’s Metastatic Breast Cancer, The Assistance Fund’s Breast Cancer, Patient Advocate Foundation’s Breast Cancer and Patient Services, Inc.’s Breast Cancer Screening funds are accepting applications.


For current information, log in to FundFinder 

Assistance Amount

$5,500 per year. Patients may apply for a second grant during their eligibility period subject to availability of funding.

Eligibility Criteria

  1. The patient must be getting treatment for metastatic breast cancer.
  2. The patient must have Medicare health insurance that covers his or her qualifying medication or product. 
  3. The patient’s medication or product must be listed on PAN’s list of covered medications.
  4. The patient’s income must fall at or below 500% of the Federal Poverty Level.
  5. The patient must reside and receive treatment in the United States or U.S. territories. (U.S. citizenship is not a requirement.)
list icon
See the list of medications covered in this program
View List  
  • Abraxane (paclitaxel protein-bound)
  • Adriamycin (doxorubicin hcl)
  • Adrucil (fluorouracil)
  • Afinitor (everolimus)
  • Anastrozole (anastrozole)
  • Androxy (fluoxymesterone)
  • Arimidex (anastrozole)
  • Aromasin (exemestane)
  • Avastin (bevacizumab)
  • Capecitabine (capecitabine)
  • Carboplatin (carboplatin)
  • Cisplatin (cisplatin)
  • Cyclophosphamide (cyclophosphamide)
  • Docefrez (docetaxel)
  • Docetaxel (docetaxel)
  • Doxil (doxorubicin hcl pegylated liposomal)
  • Doxorubicin Hcl (doxorubicin hcl)
  • Doxorubicin Hcl Liposome (doxorubicin hcl pegylated liposomal)
  • Eligard (leuprolide acetate)
  • Ellence (epirubicin hcl)
  • Epirubicin Hcl (epirubicin hcl)
  • Exemestane (exemestane)
  • Fareston (toremifene citrate)
  • Faslodex (fulvestrant)
  • Femara (letrozole)
  • Fluorouracil (fluorouracil)
  • Gemcitabine Hcl (gemcitabine hcl)
  • Gemzar (gemcitabine hcl)
  • Halaven (eribulin mesylate)
  • Herceptin (trastuzumab)
  • Ibrance (palbociclib)
  • Ixempra (ixabepilone)
  • Kadcyla (ado-trastuzumab emtansine)
  • Kisqali (ribociclib succinate)
  • Kisqali Femara Co-pack (ribociclib succinate/letrozole)
  • Letrozole (letrozole)
  • Leuprolide Acetate (leuprolide acetate)
  • Lipodox (doxorubicin hcl pegylated liposomal)
  • Lupron Depot (leuprolide acetate)
  • Lynparza (olaparib)
  • Megace (megestrol acetate)
  • Megace Es (megestrol acetate)
  • Megestrol Acetate (megestrol acetate)
  • Methotrexate (methotrexate sodium)
  • Navelbine (vinorelbine tartrate)
  • Nerlynx (neratinib maleate)
  • Paclitaxel (paclitaxel)
  • Perjeta (pertuzumab)
  • Soltamox (tamoxifen citrate)
  • Talzenna (talazoparib tosylate)
  • Tamoxifen Citrate (tamoxifen citrate)
  • Taxotere (docetaxel)
  • Tykerb (lapatinib ditosylate)
  • Verzenio (abemaciclib)
  • Vinorelbine Tartrate (vinorelbine tartrate)
  • Vitrakvi (larotrectinib sulfate)
  • Xeloda (capecitabine)
  • Zoladex (goserelin acetate)
  • Zortress (everolimus)

Diagnosis Codes:

ICD-10: C50.011, C50.012, C50.019, C50.021, C50.022, C50.029, C50.111, C50.112, C50.119, C50.121, C50.122, C50.129, C50.211, C50.212, C50.219, C50.221, C50.222, C50.229, C50.311, C50.312, C50.319, C50.321, C50.322, C50.329, C50.411, C50.412, C50.419, C50.421, C50.422, C50.429, C50.511, C50.512, C50.519, C50.521, C50.522, C50.529, C50.611, C50.612, C50.619, C50.621, C50.622, C50.629, C50.811, C50.812, C50.819, C50.821, C50.822, C50.829, C50.911, C50.912, C50.919, C50.921, C50.922, C50.929